menu
    • menu

    Company profile for Cayman Pharma s.r.o

    Cayman Pharma s.r.o-PSE
    News
    Chemist with a passion for technology

    15 Jan 2021

    // PRESS RELEASE

    Pavel Bartko: One security guard will not solve work safety as a soldier himself in the field. He must have the support of employees

    05 Oct 2020

    // PRESS RELEASE

    Coronavirus has tested the resilience of companies Ours has survived and we continue to run at full throttle

    12 Jun 2020

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Cayman pharma

    Contact Supplier

    Website

    CPhI Milan

    Booth #3H83

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.pharmacompass.com/video-pharmareel/cayman-pharma-sro/versatile-source-for-prostaglandin-apis

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Cayman Pharma is Europe's most reliable and versatile source for Prostaglandin APIs//FDA approved.

    Related CompaniesRelated Companies

    About

    Cayman Pharma is a leading European provider of cGMP prostaglandin APIs, created in 2006 from the merger of Cayman Chemical and NeraPharm, combining deep prostaglandin chemistry expertise. With nearly 60 years of experience, it uses a patented route for the prostaglandin core structure and holds GMP approvals from European and US regulators. The company supports fertility, eye care, glaucoma, and pulmonary hypertension products with validated GMP routes and regulatory support. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cayman Pharma s.r.oCzechRepublic Flag
    Country
    Country
    Czech Republic
    Address
    Address
    Práce 657, 277 11, Neratovice
    Telephone
    Telephone
    +420 313033155
    Client Email
    Email
    sales@caymanpharma.cz
    Client Website
    Website
    https://www.caymanpharma.com/home
    Linkedin
    Linkedin
    https://in.linkedin.com/company/cayman-pharma-s-r-o-
    youtube
    YouTube
    http://www.youtube.com/@caymanpharma9856
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI Milan

    Booth #3H83

    envelop Contact Supplier

    CPhI Milan

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    VLOG #PharmaReel

    read-more

    ReelPharmaVersatile Source for Prostaglandin APIsVersatile Source for Prostaglandin APIs

    Versatile Source for Prostaglandin APIs
    Versatile Source for Prostaglandin APIs

    reelVersatile Source for Prostaglandin APIs

    This PharmaReel spotlights Cayman Pharma’s expertise in Prostaglandin APIs, backed by Czech NCA (SUKL, USKVBL) and USFDA approvals. With patented technology, process excellence, and quality focus, Cayman is a trusted partner for reliable CDMO services.

    Impressions: 8497

    read-more

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/cayman-pharma-sro-party-content-84466.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/cayman-pharma-sro-party-content-40808.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/cayman-pharma-sro-party-content-54585.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Ophthalmology APIs

    read-more

      https://www.pharmacompass.com/pdf/party/content/cayman-pharma-sro-party-content-10065.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Psychedelic APIs

    read-more

      https://www.pharmacompass.com/pdf/party/content/cayman-pharma-sro-party-content-61724.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Animal Health APIs

    read-more

      https://www.pharmacompass.com/pdf/party/content/cayman-pharma-sro-party-content-24364.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Vascular APIs

    read-more

      https://www.pharmacompass.com/pdf/party/content/cayman-pharma-sro-party-content-52276.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    CGMP Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/cayman-pharma-sro-party-content-90282.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/cayman-pharma-sro-party-content-60518.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Ionizable Cationic Lipids: From R&D to API

    read-more

      https://www.pharmacompass.com/pdf/party/content/cayman-pharma-sro-party-content-60514.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate SUKL

    read-more

      https://www.pharmacompass.com/pdf/party/content/cayman-pharma-sro-party-content-81286.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate USKVBL

    read-more

      https://www.pharmacompass.com/pdf/party/content/cayman-pharma-sro-party-content-2864.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Prostaglandin market to cross US$ 1.27 bn by 2035; Liquidia’s Yutrepia okayed for pulmonary hypertension

    Prostaglandin market to cross US$ 1.27 bn by 2035; Liquidia’s Yutrepia okayed for pulmonary hypertension

    Prostaglandins are natural fatty acid compounds produced by the human body. They are made from a type of fat known as arachidonic acid and act like messengers, controlling many functions such as inflammation, blood flow, muscle contraction, and fluid drainage in the eye. Prostaglandin APIs are synthetic (lab-made) versions of natural prostaglandins that are used to create medicines. Prostaglandin-based medicines are used in obstetrics and gynecology, gastroenterology, urology, and cosmetics, and their use is also being explored in certain cardiovascular and respiratory conditions. One of the largest and most important uses of prostaglandin APIs is in ophthalmology (eye care), where they are used as first-line therapy for open-angle glaucoma (a chronic, progressive eye disease) and ocular hypertension (a condition where pressure inside the eye is consistently higher than normal). In ophthalmic applications, these drugs usually serve as prodrugs – inactive in the formulation but converted into their active form after entering the eye.According to estimates, the global prostaglandin market is valued at US$ 0.63 billion in 2025 and is poised to grow from US$ 0.68 billion in 2026 to US$ 1.27 billion by 2035, growing at a CAGR of 7.1 percent between 2026 and 2035.Prostaglandin API manufacturing is a highly specialised field, with only a few experienced manufacturers. Companies such as EUROAPI, Cayman Pharma, Chirogate International, Kyowa Pharma Chemical, Everlight Chemical, and Yonsung Fine Chemicals are key players with strong capabilities in complex chemistry.FDA allows Glaukos’ iDose TR to be re-administered for treating eye diseases; approves Liquidia’s Yutrepia The prostaglandin market continues to see steady regulatory activity and innovations. In ophthalmology, Glaukos Corporation’s iDose TR received a labelling supplement from the US Food and Drug Administration (FDA) that allows for re-administration of the medication indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). The intracameral implant was originally approved in December 2023 for single use. This update was supported by long-term safety data demonstrating good tolerability in patients with OAG and OHT. Similarly, Santen Pharmaceutical secured manufacturing and marketing approval in Japan for Setaneo (sepetaprost) ophthalmic solution 0.002% in August 2025 for the treatment of glaucoma and OHT. In April 2025, Santen also received approval in China for Tapcom (tafluprost + timolol maleate), a preservative-free fixed-dose combination therapy that lowers intraocular pressure (IOP) in patients with OAG and OHT.Beyond ophthalmology, prostaglandin APIs are also driving advancements in respiratory care. Liquidia Corporation received FDA approval in May 2025 for Yutrepia (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). While PAH is a serious and progressive disease where blood pressure in the lung arteries rises, causing them to narrow and harden, PH-ILD is a serious complication in which high blood pressure develops in the lung arteries due to lung scarring. Yutrepia is the first and only prostacyclin dry-powder formulation enabled by Liquidia’s proprietary technology.  Access the Interactive Dashboard on Prostaglandin Developments (Free Excel Available)Nicox’s drug scores phase 3 win in glaucoma, OHT; United seeks expanded approval for Tyvaso to treat pulmonary fibrosisInnovation in prostaglandins is increasingly focused on enhanced efficacy and sustained drug delivery. French ophthalmology company Nicox has reported positive phase 3 results for its ophthalmic solution NCX 470, demonstrating consistent lowering of intraocular pressure in OAG and OHT. Nicox is likely to submit a new drug application for NCX 470 sometime soon, with a potential approval and launch expected in 2027.Meanwhile, US-based SpyGlass Pharma is advancing sustained-release innovation through intraocular lens (IOL)-based and ring-based drug delivery systems. Its Bimatoprost Drug Pad–Intraocular Lens (BIM-IOL) system (currently in phase 3 trials) integrates drug delivery with cataract surgery to enable sustained therapy for up to three years. The company is also developing a preclinical Bimatoprost Drug Ring System (BIM-DRS) designed for similarly extended drug release. In respiratory indications, Insmedis progressing treprostinil palmitil inhalation powder through phase 3 trials for PH-ILD, as well as for idiopathic pulmonary fibrosis and PAH.Additionally, United Therapeutics is expanding the clinical scope of Tyvaso DPI (treprostinil). Following its global approval in 2022 for PAH, the therapy is now under regulatory review in the US and Canada for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.  Access the Interactive Dashboard on Prostaglandin Developments (Free Excel Available)Glaukos sets up new R&D facility in Alabama, Inke acquires Pharmanoid to strengthen presence in prostaglandins Several players are expanding capacities due to rising demand across ophthalmology. Glaukos Corporation is setting up a new research, development, and manufacturing facility in Huntsville, Alabama. The planned 200,000 square-foot site, to be built on a 25-acre campus in Cummings Research Park, envisages an investment of over US$ 80 million. Expected to be completed by 2030, the facility is designed to augment the company’s existing infrastructure and support long-term growth, particularly in ophthalmic therapies including sustained-release drug delivery systems.EUROAPIis undertaking a significant capacity expansion at its Budapest site. The company has committed €50 million (US$ 54.8 million) to install a new state-of-the-art production plant focused on prostaglandins. The project aims to debottleneck existing operations and introduce new multi-purpose manufacturing equipment, ultimately more than doubling the site’s prostaglandin production capacity by 2027. The expansion will also strengthen EUROAPI’s highly potent API (HPAPI) capabilities.Alongside capacity additions by established players, the market is also witnessing consolidation and capability expansion through acquisitions. For instance, Essential Pharma acquired Ventavis (iloprost trometamol) from Bayer AG, including rights to the accompanying Breelib nebuliser delivery technology. Ventavis, a prostacyclin analogue, is a well-established treatment for adult patients with primary pulmonary hypertension.Inke strengthened its presence in ophthalmology-focused high-potency APIs (HPAPIs), including prostaglandins, through the acquisition of Pharmanoid in December 2025. Backed by regulatory approvals across 25+ countries, Pharmanoid enhances Inke’s capabilities in complex API production and supports its ambition to build a leading European platform for advanced API development and manufacturing. The Barcelona facility is capable of producing and handling APIs across all potency levels while adhering to SafeBridge Scale OEB4 (Occupational Exposure Band 4) containment protocols, a classification for high-potency substances requiring strict controls to limit occupational exposure.With more than two decades of experience, Inke is recognized for innovating and manufacturing high-quality APIs, delivering expertise, safety, and excellence across inhalation, CNS, and ophthalmic therapies, while supporting pharmaceutical companies worldwide. The ophthalmic API commercial portfolio includes bimatoprost, latanoprost, tafluprost, and travoprost, while the next-generation prostaglandin analog pipeline includes bimatoprost grenod and latanoprostene bunod.  Access the Interactive Dashboard on Prostaglandin Developments (Free Excel Available)Our viewInnovation is guiding the prostaglandins market towards long-acting, sustained-release formulations and novel delivery systems. These innovations are driving steady growth in prostaglandins, while capacity expansions are strengthening capabilities in complex and highly potent APIs. Overall, this remains a niche but important market to watch. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 900

    https://www.pharmacompass.com/radio-compass-blog/prostaglandin-market-to-cross-us-1-27-bn-by-2035-liquidia-s-yutrepia-okayed-for-pulmonary-hypertension

    #PharmaFlow by PHARMACOMPASS
    14 May 2026
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Chemist with a passion for technology
    Chemist with a passion for technology

    15 Jan 2021

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/chemist-with-a-passion-for-technology-30802.pdf

    PRESS RELEASE
    15 Jan 2021
    Share Share
    Pavel Bartko: One security guard will not solve work safety as a soldier himself in the field. He must have the support of employees
    Pavel Bartko: One security guard will not solve work safety as a soldier himself in the field. He must have the support of employees

    05 Oct 2020

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/pavel-bartko-one-security-guard-will-not-solve-work-safety-as-a-soldier-himself-in-the-field-he-must-have-the-support-of-employees-69499.pdf

    PRESS RELEASE
    05 Oct 2020
    Share Share
    Coronavirus has tested the resilience of companies Ours has survived and we continue to run at full throttle
    Coronavirus has tested the resilience of companies Ours has survived and we continue to run at full throttle

    12 Jun 2020

    // PRESS RELEASE

    https://www.caymanpharma.com/news/459

    PRESS RELEASE
    12 Jun 2020
    Share Share
    Jiří Kratochvíl: Let's not forget that we also have patients without COVID-19
    Jiří Kratochvíl: Let's not forget that we also have patients without COVID-19

    07 May 2020

    // PRESS RELEASE

    https://www.caymanpharma.com/news/451

    PRESS RELEASE
    07 May 2020
    Share Share
    When the electronic time comes to the company
    When the electronic time comes to the company

    27 Mar 2020

    // PRESS RELEASE

    https://www.caymanpharma.com/news/431

    PRESS RELEASE
    27 Mar 2020
    Share Share
    What to attract employees to? The key is quality product and flexibility
    What to attract employees to? The key is quality product and flexibility

    26 Feb 2020

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/what-to-attract-employees-to-the-key-is-quality-product-and-flexibility-45354.pdf

    PRESS RELEASE
    26 Feb 2020
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    Analytical

    Discover their expertise for : Analytical

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Cayman Popup full-view
    cGMP Contract Manufacturing of API
    full-view
    Custom - Contract Manufacturing
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Cayman Pharma s.r.o and get a quotation

    Cayman Pharma s.r.o is a supplier offers 8 products (APIs, Excipients or Intermediates).

    Find Latanoprost bulk with DMF, CEP, JDMF offered by Cayman Pharma s.r.o

    Find Epoprostenol Sodium bulk with DMF, JDMF offered by Cayman Pharma s.r.o

    Find Travoprost bulk with DMF, JDMF offered by Cayman Pharma s.r.o

    Find Bimatoprost bulk with DMF offered by Cayman Pharma s.r.o

    Find Latanoprostene Bunod bulk with DMF offered by Cayman Pharma s.r.o

    Find Tafluprost bulk with DMF offered by Cayman Pharma s.r.o

    Find Cloprostenol Sodium bulk offered by Cayman Pharma s.r.o

    Find Psilocybine bulk offered by Cayman Pharma s.r.o

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search